MG
GPCR icon

Michael Gelband’s Structure Therapeutics GPCR Stock Holding History

Michael Gelband’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.2M Buy
+78,266
New +$3.46M 0.03% 553

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Michael Gelband's GPCR Position: Q2 2026 in Review

Michael Gelband opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 78,266 shares worth $4.2M. The stake represents 0.03% of the portfolio and ranks #553 among its holdings.

192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Michael Gelband held 78,266 shares of Structure Therapeutics worth $4.2M as of Q2 2026.
  • Structure Therapeutics was a new Michael Gelband position in Q2 2026.
  • Structure Therapeutics made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #553 holding.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.